10x Genomics reported second-quarter revenue of $151 million on August 6. The figure includes a $1.6 million settlement payment from Takara. Excluding that payment, revenue increased by 3% year over year to $149.4 million. The company highlighted a new instrument platform named Atera, noting that booked orders for the device have surpassed the total number of units planned for shipment in 2026.
Demand for the new platform was evident in the Catalyst Research Services program, which allows customers to test samples in 10x Genomics facilities before purchasing hardware. The company’s consumables business also expanded, with overall growth of 7% and a 16% increase in spatial consumables linked to the Xenium platform.
During the quarter, 10x Genomics acquired Proteintech Genomics to add single-cell protein panels, a capability management says will enable Atera to measure proteins and gene expression simultaneously.
Financial metrics showed cash and marketable securities rising to $552 million, an increase of $105 million from the previous year. Gross margin improved to 74% from 72%. Management raised full-year revenue guidance to a range of $610 million to $630 million.
New research partnerships with Cleveland Clinic and Lausanne University Hospital focus on identifying biomarkers for treatment response in oncology, aligning with the company’s interest in clinical diagnostics.
Conversely, revenue from the existing instrument line dropped 47% year over year. Chromium instruments saw a 46% decline, while spatial instruments fell 48%, as customers delayed purchases of older systems in anticipation of the new platform. Management expects this pause to continue, projecting a revenue decrease in the third quarter followed by an increase in the fourth.
